OTCPK:CNBI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

China BCT Pharmacy Group

Executive Summary

China BCT Pharmacy Group, Inc., through its subsidiaries, operates as an integrated pharmaceutical company in the People’s Republic of China. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has China BCT Pharmacy Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CNBI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

CNBI

2.3%

US Healthcare

0.08%

US Market


1 Year Return

-15.1%

CNBI

16.6%

US Healthcare

12.8%

US Market

Return vs Industry: CNBI underperformed the US Healthcare industry which returned 16.6% over the past year.

Return vs Market: CNBI underperformed the US Market which returned 12.8% over the past year.


Shareholder returns

CNBIIndustryMarket
7 Day0%2.3%0.08%
30 Day0%-3.0%-1.8%
90 Day-50.0%1.7%7.2%
1 Year-15.1%-15.1%18.1%16.6%15.3%12.8%
3 Year36.4%36.4%29.9%24.2%39.2%29.9%
5 Year-27.4%-27.4%53.9%43.0%88.3%67.1%

Price Volatility Vs. Market

How volatile is China BCT Pharmacy Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is China BCT Pharmacy Group undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether China BCT Pharmacy Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as China BCT Pharmacy Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine China BCT Pharmacy Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through China BCT Pharmacy Group regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is China BCT Pharmacy Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China BCT Pharmacy Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has China BCT Pharmacy Group performed over the past 5 years?

7.7%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, China BCT Pharmacy Group has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is China BCT Pharmacy Group's financial position?


In this section we usually analyse China BCT Pharmacy Group's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. China BCT Pharmacy Group has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CNBI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when China BCT Pharmacy Group's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is China BCT Pharmacy Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CNBI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CNBI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CNBI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNBI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CNBI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.3yrs

Average board tenure


CEO

Huitian Tang (58 yo)

10.75yrs

Tenure

US$425,885

Compensation

Mr. Huitian Tang has been the Chairman and Chief Executive Officer of China BCT Pharmacy Group, Inc. since January 14, 2010 and December 30, 2009 respectively. Mr. Tang has been the President of Liuzhou Ba ...


Board Members

NamePositionTenureCompensationOwnership
Huitian Tang
Chairman of the Board and Chief Executive Officer10.75yrsUS$425.89kno data
Xiaoyan Zhang
Chief Financial Officer10.67yrsUS$325.02kno data
Kam Cheung Chin
Independent Directorno dataUS$16.78kno data
Yunli Lou
Director9.5yrsno datano data
Man Wai Chiu
Independent Director10.25yrsUS$16.78kno data
Hon Keung Choi
Independent Director10.25yrsUS$16.78kno data

10.3yrs

Average Tenure

58yo

Average Age

Experienced Board: CNBI's board of directors are seasoned and experienced ( 10.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China BCT Pharmacy Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China BCT Pharmacy Group, Inc.
  • Ticker: CNBI
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: US$171.693k
  • Shares outstanding: 38.15m

Location

  • China BCT Pharmacy Group, Inc.
  • No. 102, Chengzhan Road
  • Liuzhou
  • Guangxi Zhuang Province
  • 545007
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNBIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDDec 2009

Biography

China BCT Pharmacy Group, Inc., through its subsidiaries, operates as an integrated pharmaceutical company in the People’s Republic of China. It operates through three segments: Pharmaceutical Distribution ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/21 06:11
End of Day Share Price2020/08/31 00:00
Earnings2013/03/31
Annual Earnings2012/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.